Efficacy of Baricitinib in Patients with Atopic Dermatitis and Atopic Comorbidities: Results of Pooled Data from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2)

被引：0
|
作者：
Wollenberg, Andreas [1 ]
Boguniewicz, Mark [2 ]
Travers, Jeffrey [3 ]
Thyssen, Jacob [4 ]
Goldblum, Orin [5 ]
Ball, Susan [5 ]
Sun, Luna [5 ]
Chen, Sherry [6 ]
Silverberg, Jonathan [7 ]
机构：
[1] Ludwig Maximillian Univ, Munich, Germany
[2] Natl Jewish Hlth, Denver, CO USA
[3] Wright State Univ, Dayton, OH 45435 USA
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Syneos Hlth, Raleigh, NC USA
[7] Northwestern Univ, Feinberg Sch, Evanston, IL 60208 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
610
引用
收藏
页码：AB190 / AB190
页数：1
相关论文
共 50 条
  • [41] A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) with Mild to Moderate Atopic Dermatitis
    Jacobson, Michael E.
    Myles, Ian A.
    Paller, Amy S.
    Eichenfield, Lawrence F.
    Simpson, Eric Lawrence
    DERMATOLOGY, 2024, 240 (01) : 85 - 94
  • [42] Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study
    Guttman-Yassky, Emma
    Esfandiari, Ehsanollah
    Mano, Hirotaka
    Arai, Takahiro
    Kabashima, Kenji
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [43] Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial
    Bissonnette, R.
    Poulin, Y.
    Zhou, Y.
    Tan, J.
    Hong, H. C.
    Webster, J.
    Ip, W.
    Tang, L.
    Lyle, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04) : 853 - 860
  • [44] Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial
    Ji, Linong
    Lu, Jinmiao
    Gao, Leili
    Ying, Changjiang
    Sun, Jiao
    Han, Jie
    Zhao, Wenhua
    Gao, Yunming
    Wang, Kun
    Zheng, Xin
    Xie, Daosheng
    Ding, Juping
    Zhao, Jiahong
    Yu, Qiang
    Wang, Tong
    DIABETES OBESITY & METABOLISM, 2023, 25 (12): : 3671 - 3681
  • [45] Efficacy of cariprazine in patients with bipolar depression: Results from 3 randomized, double-blind, placebo-controlled trials
    Earley, W.
    Burgess, M.
    Rekeda, L.
    McIntyre, R. S.
    Sachs, G. S.
    Yatham, L. N.
    Suppes, T.
    Tohen, M.
    Calabrese, J.
    Vieta, E.
    BIPOLAR DISORDERS, 2019, 21 : 137 - 137
  • [46] Efficacy of dupilumab treatment in atopic hand and foot dermatitis across morphological subtypes and patch test: Results from a phase 3, randomized, double-blind, placebo-controlled study
    Worm, Margitta
    Simpson, Eric L.
    Petrova, Anastasia
    Honari, Golara
    Soong, Weily
    Pinter, Andreas
    Masuda, Koji
    Chen, Zhen
    Dubost-Brama, Ariane
    Bansal, Ashish
    Korotzer, Andrew
    Rossi, Ana B.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2024, 54 (10): : 804 - 804
  • [47] Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial
    Guttman-Yassky, E.
    Bahadori, L.
    Brooks, L.
    Clark, K. L.
    Grindebacke, H.
    Ho, C. N.
    Katial, R.
    Pham, T. -H.
    Walton, C.
    Datto, C. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : E1211 - E1214
  • [48] Tralokinumab significantly reduces Staphylococcus aureus colonization in adult patients with moderate-to-severe atopic dermatitis (AD): Results from a Phase 2b, randomized, double-blind, placebo-controlled study (NCT02347176)
    Guttman-Yassky, E.
    Silverberg, J. I.
    Fensholdt, J.
    Lindegaard, K. K.
    Wollenberg, A.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 41 - 41
  • [49] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials
    Silverberg, Jonathan
    Thaci, Diamant
    Seneschal, Julien
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric
    Chu, Chia-Yu
    Liu, Zhuqing
    Lima, Renata Gontijo
    Pillai, Sreekumar
    Guttman-Yassky, Emma
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 62 - 62
  • [50] EFFICACY AND SAFETY OF BARICITINIB IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH CYCLOSPORINE FAILURE, INTOLERANCE, OR CONTRAINDICATION: 52-WEEK RESULTS FROM THE BREEZE-AD 4 TRIAL
    Bieber, Thomas
    Reich, Kristian
    Paul, Carle
    Tsunemi, Yuichiro
    Augustin, Matthias
    Lacour, Jean-Philippe
    Ghislain, Pierre-Dominique
    Dutronc, Yves
    Brinker, Dennis
    DeLozier, Amy M.
    Yang, Fan Emily
    Meskimen, Eric
    Janes, Jonathan M.
    Eyerich, Kilian
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 63 - 63
12345